1-3 of 3
Allison Barraclough
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study

Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoff Chong, Denise Lee, Michael Gilbertson, Tineke Fancourt, Kate Manos, David S. Ritchie, Rachel M. Koldej, Andrew M. Scott, Colm Keane, Eliza A. Hawkes
Journal: Blood Advances
Blood Adv (2025) 9 (6): 1432–1441.
https://doi.org/10.1182/bloodadvances.2024015487
Published: 2025
Includes: Supplemental data
Journal Articles

Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review

Luke Wang, Eliza Chung, Cameron Wellard, Allison Barraclough, Belinda A Campbell, Geoffrey Chong, Pietro R Di Ciaccio, Gareth P. Gregory, Greg Hapgood, Anna M. Johnston, Constantine S. Tam, Stephen Opat, Erica M Wood, Zoe McQuilten, Eliza A Hawkes
Journal: Blood Advances
Blood Adv bloodadvances.2024015072.
https://doi.org/10.1182/bloodadvances.2024015072
Published: 2025
Includes: Supplemental data
Journal Articles

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Clinical Trials & Observations
Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Jorne Biccler, Joseph M. Connors, David W. Scott, Maher K. Gandhi, Kerry J. Savage, Tarec El-Galaly, Diego Villa, Chan Yoon Cheah
Journal: Blood Advances
Blood Adv (2019) 3 (13): 2013–2021.
https://doi.org/10.1182/bloodadvances.2019000251
Published: 2019